BIOQUAL Presents Unaudited Financial Results for First Quarter of Fiscal Year 2024

BIOQUAL, Inc. (OTC Pink:BIOQ) www.bioqual.com:

Three Months Ended

August 31,

 

2023

2022

Revenue

$

15,578,922

$

15,810,574

 

Income Before Income Tax

$

1,241,183

$

1,955,660

 

Net Income

$

899,483

$

1,383,560

 

Basic Earnings per Share
   of Common Stock

 

$

 

1.01

 

$

 

1.55

 

Diluted Earnings per Share
   of Common Stock

 

$

 

1.01

 

$

 

1.55

 

Weighted Average
   Number of Shares Outstanding
   For Basic Earnings Per Share

 

 

 

 

 

894,416

 

 

 

 

 

894,416

 

Weighted Average
   Number of Shares Outstanding
   For Diluted Earnings Per Share

 

 

 

 

 

894,406

 

 

 

 

 

894,405

For more detail related to the fiscal year 2024 unaudited first quarter results, please visit our web site at www.bioqual.com.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. The forward-looking statements are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to obtain sufficient numbers of animal models; the availability of adequate numbers of employees; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231020643856/en/

The Bioqual Stock at the time of publication of the news with a fall of -1,67 % to 59,00USD on Nasdaq OTC stock exchange (09. Oktober 2023, 19:18 Uhr).